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ABSTRACT  
 
Background and Aim: Although methadone, an opioid agonist, has been an 
effective medication used to treat opioid use disorder for over 40 years, recent 
studies have found that methadone was identified in more than a quarter of 
prescription opioid-related deaths among people who use illicit drugs in 
Vancouver, Canada. Thus, we sought to longitudinally examine the availability of 
diverted methadone among people who inject drugs (PWID).  
 
Design and Methods: Data were collected from three prospective cohorts of PWID 
in Vancouver, Canada between December 2005 and May 2015. Multivariable 
generalized estimating equation logistic regression was used to identify temporal 
trends in the immediate availability of diverted methadone (defined as the ability 
to acquire illicit methadone in <10 minutes).  
Results: A total of 2092 participants, including 727 (34.8%) women, were included 
in the present study. In the multivariable analyses after adjusting for a range of 
potential confounders, later calendar year (adjusted odds ratio [AOR] = 1.21 per 
year; 95% confidence interval [CI]: 1.19–1.23) was independently and positively 
associated with reporting immediate availability of diverted methadone.  
 
Conclusions: We observed a significant increase in the reported availability of 
diverted methadone among PWID over a ten-year follow-up period. Further 
research is needed to identify strategies to limit methadone diversion and assess 
the impact of alternative medications that are equally effective but safer, such as 
buprenorphine/naloxone.   
 
Word Count: 221 
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1. INTRODUCTION 
In the past decade, opioid use disorder (OUD) has become a major public 
health challenge in Canada and the United States (Gomes et al., 2011; United 
Nations Office on Drugs and Crime, 2014). Increases in the availability of heroin 
and other illicit opioids, significant increase in opioid prescription, and diversion 
of prescription opioids have contributed to the morbidity and mortality associated 
with OUD (Carter, 2012; Compton, Jones, & Baldwin, 2016; King, Fraser, Boikos, 
Richardson, & Harper, 2014; Nosyk et al., 2012). Specific consequences of OUD 
include increased risk of blood-borne disease including viral hepatitis and HIV, as 
well as opioid related overdose and death (Peters et al., 2016; Suryaprasad et al., 
2014; Zibbell, Hart-Malloy, Barry, Fan, & Flanigan, 2014) (Dart et al., 2015; Fischer, 
Jones, & Rehm, 2013; Gomes et al., 2014). 
Methadone maintenance therapy (MMT) is a longstanding 
pharmacotherapy prescribed for OUD (Nosyk, Marsh, Sun, Schechter, & Anis, 
2010). In British Columbia, Canada, MMT clinical practice guidelines were 
introduced in 1995 and have been expanded to include strategies to monitor and 
titrate daily dosing, treatment initiation, maintenance dosing, and take-home 
doses (College of Physicians and Surgeons of British Columbia, 2005; Payte, 1995). 
With an exemption under section 56 of the Controlled Drugs and Substances Act, 
primary care physicians can prescribe methadone that is dispensed through 
community pharmacies. Between 1996 and 2016, the number of patients receiving 
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methadone has increased nearly six-fold in British Columbia (Nosyk et al., 2010; 
Office of the Provincial Health Officer, 2017). MMT has been shown to effectively 
decrease illicit opioid use, reduce rates of hepatitis C and HIV infection among 
people who inject drugs (PWID) and improve antiretroviral adherence and 
virologic outcomes among people living with HIV (Gowing, Farrell, Bornemann, 
Sullivan, & Ali, 2011; Low et al., 2016; MacArthur et al., 2012; Perlman et al., 2015).  
However, the risk of toxicity and adverse events associated with 
methadone is greater than other prescription opioids due to the narrow 
therapeutic index, long and highly variable half-life, and potential for drug-drug 
interactions (British Columbia Centre on Substance Use, 2017; Webster et al., 2011). 
In the United States, the rate of methadone related emergency room visits has been 
found to be approximately six times greater than prescription oxycodone and 23 
times greater than prescription hydrocodone after adjusting for the total number 
of prescriptions dispensed (Substance Abuse and Mental Health Services 
Administration 2013; Webster et al., 2011). While methadone prescription has 
been linked to diversion and methadone-related overdose in several countries, 
some settings have successfully expanded methadone programs without an 
increase in mortality risk (Fugelstad, Lars, & Thiblin, 2010; Iwersen-Bergmann 
et al., 2014; Morgan, Griffiths, & Hickman, 2006; Strang, Hall, Hickman, & Bird, 
2010). In the United States, methadone was identified in more than a third of 
opioid-related deaths in 2009 despite representing 5-19% of all opioid 
prescriptions per year (Centers for Disease & Prevention, 2012). Although recent 
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data have shown a decrease in methadone-related overdose deaths in the United 
States, they still accounted for 3400 overdose deaths in 2014 (Jones, Baldwin, 
Manocchio, White, & Mack, 2016). A recent study from British Columbia, Canada, 
reported similar results and found that methadone was involved in 25% of opioid-
related deaths (Gladstone, Smolina, & Morgan, 2016). Thus, there seems to be 
regional differences in whether or not methadone prescription is associated 
with increases in overdose mortality.  
Many factors have been consistently associated with methadone-related 
overdose. These factors include non-prescribed, diverted and illicit use of 
methadone, as well as polysubstance use involving alcohol and benzodiazepines 
(Duffy P, 2014; Jones et al., 2016; Strang et al., 2010; Tjagvad et al., 2016). However, 
few studies have examined the diverted methadone market. A recent study from 
the United States indicated methadone prescription for pain, as opposed to 
treatment for OUD, was the primary source of diversion, although other 
evidence indicates that this may be moderated by regional differences in 
prescription programs and the accessibility of methadone (Johnson & Richert, 
2015b; Jones et al., 2016). While the primary source of methadone diversion in 
Vancouver, Canada is uncertain, previous studies reported that there were 344 
active prescribers of methadone for OUD in 2012, compared to 685 who were 
authorized to prescribe methadone for analgesia, with a significant proportion 
being pain or palliative care specialists (Hawley, 2012; Office of the Provincial 
Health Officer, 2017). Given the association between methadone diversion and 
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methadone-related overdose, we sought to longitudinally examine the 
availability of diverted methadone among three community-recruited prospective 
cohorts of PWID in Vancouver, British Columbia.   
2. METHODS 
2.1 Study Procedure 
The data for this investigation were obtained from three ongoing open 
prospective cohort studies of people who use drugs: the Vancouver Injection Drug 
Users Study (VIDUS), the AIDS Care Cohort to evaluate Exposure to Survival 
Services (ACCESS), and the At-Risk Youth Study (ARYS). These studies have been 
described in detail previously (Tyndall et al., 2003; Wood, Stoltz, Montaner, & 
Kerr, 2006). To provide a brief overview, VIDUS enrolls HIV-negative people who 
inject drugs, ACCESS enrolls HIV-positive people who use illicit drugs other than 
or in addition to cannabis (Strathdee et al., 1998; Wood et al., 2009) and ARYS 
enrolls street-involved youth who use illicit drugs, other than or in addition to 
cannabis, and are 14-26 years old (Wood et al., 2006). Participants in all three 
studies have to reside in the Greater Vancouver region and provide informed 
consent at study enrollment. 
Data related to sociodemographic information, substance use patterns, HIV 
risk behavior and engagement with health and social services including addiction 
treatment were collected through an interview-administered questionnaire at 
baseline and semi-annually over follow-up. All three studies applied harmonized 
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recruitment and data collection methods to facilitate pooled analyses. Participants 
are remunerated $30 CAD for each study visit. These studies have been approved 
by the University of British Columbia/Providence Health Care Research Ethics 
Board.  
2.2 Participants and Outcome Measure 
This study included all VIDUS, ACCESS and ARYS participants aged ≥18 
years who had reported ever injecting drugs or initiated injecting during follow-
up, completed at least one study visit between December 2005 and May 2015, had 
ever used heroin or any prescription opioid by injection or non-injection, and 
provided a valid answer to questions regarding the availability of diverted 
methadone. The sample was restricted to people who inject drugs or people with 
a history of injection drug use since they are at a high risk of experiencing harms 
associated with diverted methadone such as overdosing (Kerr et al., 2007). The 
primary outcome of interest was diverted methadone availability from street-
based sources, which was derived from a question, “How difficult would it be for 
you to get street methadone right now in the area where you typically obtain your 
drugs?” The five response options included (1) within 10 minutes; (2) within 90 
minutes; (3) within a day; (4) in more than a day; (5) could not access this drug. 
These categories were collapsed to create a three-level categorical variable for this 
study: (1) immediate availability (within 10 minutes); (2) delayed availability (i.e., 
> 10 minutes); and (3) not available. Since very few participants selected 
responses (2)-(4) (i.e., within 90 minutes; within a day; in more than a day), these 
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categories were collapsed to create a three-level categorical variable for this study: 
1) immediate availability (within 10 minutes); (2) delayed availability (i.e., > 10 
minutes); and (3) not available. Retaining response options with small sample 
sizes can lead to unstable effect estimates, and combining these response 
options mitigated this issue (MacCallum, 1999). We examined correlates of 
immediate and delayed availability of diverted methadone, respectively, against 
no availability. 
2.3 Explanatory Variables 
 In order to examine temporal trends of the availability of diverted 
methadone, we included calendar year of interview (per year later) as the primary 
explanatory variable. The selection of additional explanatory variables that may 
impact the association between the primary explanatory variable and the 
availability of diverted methadone was based on existing literature (Hadland et 
al., 2010; Lake et al., 2015; Nosyk et al., 2012). These variables included socio-
demographic factors such as age (per 10 years older), sex (male vs. female), 
ethnicity/ancestry (white vs. others), residing in the Downtown Eastside (DTES) 
neighborhood of Vancouver which contains a large open drug scene (yes vs. no), 
cohort designation (ARYS vs. ACCESS vs. VIDUS [the reference category]) and 
homelessness (yes vs. no). Drug use patterns included: crack smoking (≥ daily vs. 
< daily); injection heroin use (≥ daily vs. < daily); injection cocaine use (≥ daily vs. 
< daily); injection crystal methamphetamine use (≥ daily vs. < daily); injection of 
prescription opioids (≥ daily vs. < daily); and non-fatal overdose (yes vs. no). 
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Variables related to health and social service utilization included: enrollment in 
MMT (yes vs. no), and having tried but been unable to access addiction treatment 
services (yes vs. no or never tried). Other social and structural exposures included: 
incarceration (yes vs. no); involvement in drug dealing (yes vs. no); and 
involvement in sex work (yes vs. no). Variable definitions were consistent with 
previous studies and all behavioral variables referred to the previous 6 months 
(Wood et al., 2001). 
2.4 Statistical Analysis 
 As a first step, we analyzed the baseline sample characteristics stratified by 
availability of diverted methadone (immediate vs. delayed vs. no availability), 
using Cochran-Armitage trend test for categorical variables and Kruskal-Wallis 
test for continuous variables. We also graphically illustrated temporal trends in 
the availability during the study period. Since repeated measures were available 
for each participant, we applied generalized estimating equation (GEE) logistic 
regression for the analysis of correlated data. By using an exchangeable correlation 
structure that adjusts for multiple observations for each participant, this method 
identified factors associated with the outcome across the entire study period. The 
initial multivariable model included all explanatory variables associated with 
diverted methadone availability at the level of p < 0.10 in bivariable analyses. 
Through a manual stepwise approach, reduced models were built by removing 
one secondary explanatory variable at a time that produced the smallest relative 
change in the calendar year coefficient. This process was repeated until the 
 11 
minimum change in the calendar year coefficient surpassed five percent. The 
objective of this technique is to retain covariates with a larger relative impact on 
the association between the primary explanatory variable and the outcome 
(Maldonado & Greenland, 1993).  
We also performed a sub-analysis to examine changes in the self-reported 
price of diverted methadone during the study period. The median price of 
diverted methadone was presented for each calendar year. All statistical analyses 
were performed using SAS version 9.4 (SAS Institute, USA). All tests of 
significance were two sided. 
3. RESULTS 
During the study period (December 2005 and May 2015), a total of 2092 
participants enrolled in the VIDUS, ACCESS or ARYS were eligible for the present 
study. The median age of participants was 37.3 (interquartile range [IQR] = 26.2-
45.9) years at baseline. Seven hundred and twenty-seven (34.8%) were females and 
1324 (63.3%) were white. Participants completed a median of six study visits (IQR 
= 2-12) and the median observation time per participant was 49.0 months (IQR = 
12.0–92.0). At baseline, 601 (28.7%) participants reported having immediate access 
to diverted methadone, 387 (18.5%) individuals reported delayed availability, and 
1104 (52.8%) participants were not able to access diverted methadone.  
Baseline characteristics of the study sample stratified by diverted 
methadone availability are shown in Table 1. Factors that differed across diverted 
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methadone availability strata included age, sex, homelessness, DTES residence, 
involvement in drug dealing, prescription opioid injection, participation in MMT 
and being unable to access addiction treatment (all p < 0.05). Unadjusted temporal 
trends in the availability of diverted methadone are illustrated in Figure 1. 
Table 2 includes two models showing the bivariable and multivariable GEE 
analyses of the temporal trends of the availability of diverted methadone. Model 
1 analyzed trends of the immediate availability (vs. not available) and the adjusted 
analysis revealed that calendar year remained independently and positively 
associated with immediate availability (adjusted odds ratio [AOR] = 1.21; 95% 
confidence interval [CI]: 1.19–1.23). Model 2 analyzed trends of the delayed 
availability (vs. not available) and in the adjusted model, the calendar year (AOR 
= 1.21; 95% CI: 1.19–1.23) was also independently and positively associated with 
delayed availability. The median self-reported price of diverted methadone 
remained at $10 CAD per 100mg in every calendar year of follow-up.  
 
4. DISCUSSION 
 In the present study, we observed a significant increase in the reported 
availability of diverted methadone among a community-recruited sample of 
PWID in Vancouver between 2005 and 2015 even after adjustment for a range of 
potential demographic, behavioural and social-structural confounders. The price 
of diverted methadone remained consistent at $10 CAD per 100mg over the ten-
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year follow-up period, with a median price of $10 CAD per 100mg reported at 
every year of the study period. This price was substantially less than that 
identified from studies in the United States, which reported a price of 
approximately $20 US per 80mg dose (Gwin Mitchell et al., 2009).  
A number of existing studies have contextualized the illicit market for 
methadone and buprenorphine (Cicero & Inciardi, 2005; Spunt, 1986). This 
market is different from the trafficking of other illicit opiates such as heroin, in 
that it consists of several individuals, primarily, patients undergoing opioid 
agonist therapy, who are selling small quantities of their prescription 
medication (Agar, 1977; Fountain, Strang, Gossop, Farrell, & Griffiths, 2000). A 
number of individual, social and structural risk factors for diversion have also 
been identified. Three consistently recognized risk factors for a patient 
diverting their medication include current illicit drug use, previous experience 
of purchasing illicit methadone or buprenorphine and socializing with active 
drug users (Johnson & Richert, 2015b). Supervised dosing and strict collection 
routines were associated with a decreased risk of diversion in some studies, yet 
other studies did not report this association to be significant (Dale-Perera, 2012; 
Duffy & Baldwin, 2012; Spunt, 1986; Winstock, Lea, & Sheridan, 2008). Specific 
diversion methods have been understudied, but obtaining more than one 
prescription (multiple prescription) and exaggerating the severity of drug 
addiction to receive a higher dose (overprescription) have been reported as 
strategies by methadone patients (Fountain, 1998). The two primary motives for 
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diversion include a financial need, which may or may not involve supporting 
existing drug use, and altruistic motives to support others who are experiencing 
withdrawal. Ethnographic researchers have identified that people who use 
drugs often develop a norm system where it is considered unethical to not share 
drugs with friends or acquaintances who are suffering from withdrawal. This 
has been termed ‘a moral economy of sharing’ that is based on empathizing with 
others in withdrawal and can also be influenced by the expectation that the 
recipient will pay for the medication (Bourgois, 1998; Bourgois, & Schonberg, 
2009; Havnes, Clausen, & Middelthon, 2013). The altruistic motive may be a 
more significant factor since a previous study reported ‘helping others’ was 
cited as a motive for diversion by 90% of participants while only 40% reported 
‘financial need’ as the purpose (Johnson & Richert, 2015c) 
Increased diversion of methadone from opioid agonist therapy has been 
associated with methadone-related fatalities in several countries (Jones et al., 
2016; Morgan et al., 2006; Seymour et al., 2003; Strang et al., 2010). Our results 
suggest that methadone diversion may have increased between 2005 and 2015, 
coinciding with a steady expansion of MMT programs in this setting during this 
period (College of Physicians and Surgeons of British Columbia, 2014). During the 
study period, the total number of patients receiving methadone in British 
Columbia increased from approximately 8,000 in 2005, to 16,900 in 2015 (Office 
of the Provincial Health Officer, 2017) (Office of the Provincial Health Officer, 
2013). However, between 2006/2007 and 2007/2008, the number of active 
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methadone prescribers decreased from over 400 to less than 300. This may be 
reflected in our trend data (Figure 1), which indicate a plateau in the availability 
of illicit methadone from 2007 to 2011. Between 2011 and 2015, the number of 
active opioid agonist therapy prescribers increased from 328 to 401 (Office of 
the Provincial Health Officer, 2013; Office of the Provincial Health Officer, 
2017). 
In addition to concerns regarding methadone diversion, the risk of toxicity 
and adverse events associated with methadone provoked policy change for the 
treatment of OUD. In 2017, health authorities in British Columbia also released 
new OUD treatment guidelines, which recommended replacing methadone with 
buprenorphine-naloxone as the preferred first-line opioid agonist therapy due to 
the improved public safety profile with similar treatment efficacy (British 
Columbia Centre on Substance Use, 2017; Dunlap & Cifu, 2016).  This guideline 
also proposed a range of more stringent guidelines including urine drug screening 
and unannounced medication checks for those with take home dosing as a strategy 
to reduce diversion. While our findings provide support for such change, the 
control and support measures should incorporate existing evidence from illicit 
methadone markets. Increased dosing supervision significantly reduced 
methadone-related mortality among methadone programs in Scotland and 
England, yet stringent supervision can also decrease the autonomy of patients, 
be perceived as an indignity and create an obstacle to gainful employment 
(Johnson & Richert, 2015b; Morgan et al., 2006; Strang et al., 2010). Patients who 
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are regular diverters also seem to be relatively unaffected by the threat of 
sanctions, which suggests that broad increases in controls may have little effect 
on these diverters and impose unnecessary restrictions on rule following 
patients (Johnson & Richert, 2015b). A more promising strategy for minimizing 
diversion may be improved management of comorbid psychological and 
physical health issues among opioid agonist therapy patients. Ongoing illicit 
drug use and heavy alcohol consumption are associated with diversion, and may 
represent forms of self-medication for unmanaged psychological and physical 
symptoms. Sustained follow-up with patients to evaluate dosing protocols and 
side effects is also recommended since these issues are potential triggers for 
diversion (Johnson & Richert, 2015b). Increasing the accessibility of 
buprenorphine-naloxone in opioid agonist therapies is also likely to improve 
health outcomes among patients with OUD.  
Buprenorphine-naloxone is generally viewed to be equally effective for 
reducing illicit opioid use and sustaining treatment enrolment as methadone 
(Kakko et al., 2007; Mattick, Breen, Kimber, & Davoli, 2014; Nielsen et al., 2016). 
The advantages of buprenorphine-naloxone include a decreased risk of overdose 
due to its partial agonist effect, reduced public-health risk with diversion and 
injection based on the naloxone component, milder side effect profile and fewer 
drug-drug interactions (Bell, Butler, Lawrance, Batey, & Salmelainen, 2009; Chou, 
Weimer, & Dana, 2014; D'Amore et al., 2011). In addition, buprenorphine-
naloxone may be more cost effective than methadone since the shorter induction 
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period and more flexible take-home dosing schedules reduce pharmacy 
dispensing costs and require fewer clinical visits to achieve a stable dose 
(Auriacombe, Franques, & Tignol, 2001; CADTH Rapid Response Reports, 2013). 
Although there is a decreased risk of diversion with buprenorphine-naloxone 
due to a lower abuse potential and lower street value, diversion and misuse of 
buprenorphine-naloxone is still a concern for opioid agonist therapy programs 
(Johnson & Richert, 2015a). A recent study of patients receiving buprenorphine 
for opioid detoxification found that sharing medication was perceived as a 
normative behaviour and 50% of the patients studied reported sharing their 
medication in the past (Kenney, Anderson, Bailey, & Stein, 2017). There is 
evidence that methadone may be preferable to buprenorphine-naloxone for 
individuals at a high risk of dropout or for those who continue to experience 
withdrawal symptoms despite receiving an optimal buprenorphine-naloxone 
dose (Srivastava, Kahan, & Nader, 2017). Buprenorphine-naloxone induction can 
also produce severe precipitated withdrawal if the induction is done incorrectly, 
which does not occur with methadone treatment (Rosado, Walsh, Bigelow, & 
Strain, 2007). However, the partial agonist effect of buprenorphine-naloxone 
makes it more manageable for patients to switch from buprenorphine-naloxone to 
methadone if needed, which supports buprenorphine-naloxone as the preferred 
first-line option if contraindications are not present (Breen et al., 2003; Walsh et al., 
1995). Based on the many advantages of buprenorphine-naloxone over 
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methadone, these guidelines may help to alleviate morbidity and mortality among 
PWID living with OUD in our setting.  
The major strength of this study is the prospective cohort design, which 
permitted the analysis of multiple independent correlates of diverted methadone 
availability over a ten-year follow-up period. This study also has several 
limitations. Since the participants were not randomly recruited, these results may 
not be generalizable to PWID in this and other settings. While self-report methods 
generally provide valid and reliable measurements among PWID, socially 
desirable responding and recall bias remain concerns (Darke, 1998). Lastly, there 
is a possibility that residual confounding may have impacted the associations with 
diverted methadone availability since this is an observational design.  
In summary, we found that the availability of diverted methadone among 
PWID significantly increased between 2005 and 2015. Given the increasing 
concerns of diverted methadone and methadone-related overdose, it is 
encouraging that buprenorphine-naloxone has been endorsed as a preferred first-
line treatment for OUD. Since methadone is still recommended for patients who 
are ineligible for buprenorphine-naloxone, interventions to reduce methadone 
diversion must consider how treatment access for those seeking treatment for 
OUD will be affected. Local guidelines have recently recommended strategies to 
reduce diversion, and future evaluation should examine the impacts of these 
changes (British Columbia Centre on Substance Use, 2017).  
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Dale-Perera, A., Goulão, J., & Stõver, H. (2012). Quality of care provided to 
patients receiving opioid maintenance treatment in Europe: Results from the 
EQUATOR analysis. Heroin Addiction and Related Clinical Problems, 14, 23-38.  
Darke, S. (1998). Self-report among injecting drug users: a review. Drug Alcohol 
Depend, 51(3), 253-263; discussion 267-258.  
Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher-
Bartelson, B., & Green, J. L. (2015). Trends in opioid analgesic abuse and 
mortality in the United States. N Engl J Med, 372(3), 241-248. doi: 
10.1056/NEJMsa1406143 
Duffy, P., & Baldwin, H. (2012). The nature of methadone diversion in England: a 
Merseyside case study. Harm Reduct J, 9, 3. doi: 10.1186/1477-7517-9-3 
Duffy P, M. A. (2014). Use and diversion of illicit methadone — under what 
circumstances does it occur, and potential risks associated with continued use of 
other substances. J Subst Abuse., 19(1-2), 48-55.  
Dunlap, B., & Cifu, A. S. (2016). Clinical Management of Opioid Use Disorder. 
JAMA, 316(3), 338-339. doi: 10.1001/jama.2016.9795 
 22 
Fischer, B., Jones, W., & Rehm, J. (2013). High correlations between levels of 
consumption and mortality related to strong prescription opioid analgesics in 
British Columbia and Ontario, 2005-2009. Pharmacoepidemiol Drug Saf, 22(4), 438-
442. doi: 10.1002/pds.3404 
Fountain J, G. P., Farrell M, Gossop M, Strang J. . (1998). Diversion tactics: how a 
sample of drug misusers in treatment obtained surplus drugs to sell on the illicit 
market. Int J Drug Policy, 9(3), 159-167.  
Fountain, J., Strang, J., Gossop, M., Farrell, M., & Griffiths, P. (2000). Diversion of 
prescribed drugs by drug users in treatment: analysis of the UK market and new 
data from London. Addiction, 95(3), 393-406.  
Fugelstad, A., Lars, A. J., & Thiblin, I. (2010). [More and more methadone deaths. 
"Leakage" from ongoing more liberal treatment programs might be a cause]. 
Lakartidningen, 107(18), 1225-1228.  
Gladstone, E. J., Smolina, K., & Morgan, S. G. (2016). Trends and sex differences 
in prescription opioid deaths in British Columbia, Canada. Inj Prev, 22(4), 288-
290. doi: 10.1136/injuryprev-2015-041604 
Gomes, T., Juurlink, D. N., Dhalla, I. A., Mailis-Gagnon, A., Paterson, J. M., & 
Mamdani, M. M. (2011). Trends in opioid use and dosing among socio-
economically disadvantaged patients. Open Med, 5(1), e13-22.  
Gomes, T., Mamdani, M. M., Dhalla, I. A., Cornish, S., Paterson, J. M., & Juurlink, 
D. N. (2014). The burden of premature opioid-related mortality. Addiction, 109(9), 
1482-1488. doi: 10.1111/add.12598 
Gowing, L., Farrell, M. F., Bornemann, R., Sullivan, L. E., & Ali, R. (2011). Oral 
substitution treatment of injecting opioid users for prevention of HIV infection. 
Cochrane Database Syst Rev(8), CD004145. doi: 10.1002/14651858.CD004145.pub4 
Gwin Mitchell, S., Kelly, S. M., Brown, B. S., Schacht Reisinger, H., Peterson, J. A., 
Ruhf, A., . . . Schwartz, R. P. (2009). Uses of diverted methadone and 
buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J 
Addict, 18(5), 346-355. doi: 10.3109/10550490903077820 
Hadland, S. E., Kerr, T., Marshall, B. D., Small, W., Lai, C., Montaner, J. S., & 
Wood, E. (2010). Non-injection drug use patterns and history of injection among 
street youth. Eur Addict Res, 16(2), 91-98. doi: 10.1159/000279767 
Havnes, I. A., Clausen, T., & Middelthon, A. L. (2013). 'Diversion' of methadone 
or buprenorphine: 'harm' versus 'helping'. Harm Reduct J, 10, 24. doi: 
10.1186/1477-7517-10-24 
 23 
Hawley, P. (2012). Methadone for pain in palliative care. British Columbia Medical 
Journal, 54(6), 298-301.  
Iwersen-Bergmann, S., Jungen, H., Andresen-Streichert, H., Muller, A., Elakkary, 
S., Puschel, K., & Heinemann, A. (2014). Intravenous methadone application as a 
serious risk factor for an overdose death: methadone-related fatalities in 
Hamburg from 2007 to 2012. Int J Legal Med, 128(5), 751-764. doi: 10.1007/s00414-
014-1017-x 
Johnson, B., & Richert, T. (2015a). Diversion of methadone and buprenorphine by 
patients in opioid substitution treatment in Sweden: prevalence estimates and 
risk factors. Int J Drug Policy, 26(2), 183-190. doi: 10.1016/j.drugpo.2014.10.003 
Johnson, B., & Richert, T. (2015b). Diversion of methadone and buprenorphine 
from opioid substitution treatment: patients who regularly sell or share their 
medication. J Addict Dis, 34(1), 1-17. doi: 10.1080/10550887.2014.975617 
Johnson, B., & Richert, T. (2015c). Diversion of methadone and buprenorphine 
from opioid substitution treatment: the importance of patients' attitudes and 
norms. J Subst Abuse Treat, 54, 50-55. doi: 10.1016/j.jsat.2015.01.013 
Jones, C. M., Baldwin, G. T., Manocchio, T., White, J. O., & Mack, K. A. (2016). 
Trends in Methadone Distribution for Pain Treatment, Methadone Diversion, 
and Overdose Deaths - United States, 2002-2014. MMWR Morb Mortal Wkly Rep, 
65(26), 667-671. doi: 10.15585/mmwr.mm6526a2 
Kakko, J., Gronbladh, L., Svanborg, K. D., von Wachenfeldt, J., Ruck, C., 
Rawlings, B., . . . Heilig, M. (2007). A stepped care strategy using buprenorphine 
and methadone versus conventional methadone maintenance in heroin 
dependence: a randomized controlled trial. Am J Psychiatry, 164(5), 797-803. doi: 
10.1176/ajp.2007.164.5.797 
Kenney, S. R., Anderson, B. J., Bailey, G. L., & Stein, M. D. (2017). The 
relationship between diversion-related attitudes and sharing and selling 
buprenorphine. J Subst Abuse Treat, 78, 43-47. doi: 10.1016/j.jsat.2017.04.017 
Kerr, T., Fairbairn, N., Tyndall, M., Marsh, D., Li, K., Montaner, J., & Wood, E. 
(2007). Predictors of non-fatal overdose among a cohort of polysubstance-using 
injection drug users. Drug Alcohol Depend, 87(1), 39-45. doi: 
10.1016/j.drugalcdep.2006.07.009 
King, N. B., Fraser, V., Boikos, C., Richardson, R., & Harper, S. (2014). 
Determinants of increased opioid-related mortality in the United States and 
Canada, 1990-2013: a systematic review. Am J Public Health, 104(8), e32-42. doi: 
10.2105/AJPH.2014.301966 
 24 
Lake, S., Hayashi, K., Buxton, J., Milloy, M. J., Dong, H., Wood, E., . . . Kerr, T. 
(2015). The effect of prescription opioid injection on the risk of non-fatal overdose 
among people who inject drugs. Drug Alcohol Depend, 156, 297-303. doi: 
10.1016/j.drugalcdep.2015.09.026 
Low, A. J., Mburu, G., Welton, N. J., May, M. T., Davies, C. F., French, C., . . . 
Vickerman, P. (2016). Impact of Opioid Substitution Therapy on Antiretroviral 
Therapy Outcomes: A Systematic Review and Meta-Analysis. Clin Infect Dis, 
63(8), 1094-1104. doi: 10.1093/cid/ciw416 
MacArthur, G. J., Minozzi, S., Martin, N., Vickerman, P., Deren, S., Bruneau, J., . . 
. Hickman, M. (2012). Opiate substitution treatment and HIV transmission in 
people who inject drugs: systematic review and meta-analysis. BMJ, 345, e5945. 
doi: 10.1136/bmj.e5945 
MacCallum, R. C., Widaman, K. F., Zhang, S., & Hong, S. (1999). Sample size in 
factor analysis. Psychol Methods, 4(1), 84-99.  
Maldonado, G., & Greenland, S. (1993). Simulation study of confounder-selection 
strategies. Am J Epidemiol, 138(11), 923-936.  
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine 
maintenance versus placebo or methadone maintenance for opioid dependence. 
Cochrane Database Syst Rev(2), CD002207. doi: 10.1002/14651858.CD002207.pub4 
Morgan, O., Griffiths, C., & Hickman, M. (2006). Association between availability 
of heroin and methadone and fatal poisoning in England and Wales 1993-2004. 
Int J Epidemiol, 35(6), 1579-1585. doi: 10.1093/ije/dyl207 
Nielsen, S., Larance, B., Degenhardt, L., Gowing, L., Kehler, C., & Lintzeris, N. 
(2016). Opioid agonist treatment for pharmaceutical opioid dependent people. 
Cochrane Database Syst Rev(5), CD011117. doi: 10.1002/14651858.CD011117.pub2 
Nosyk, B., Marsh, D. C., Sun, H., Schechter, M. T., & Anis, A. H. (2010). Trends in 
methadone maintenance treatment participation, retention, and compliance to 
dosing guidelines in British Columbia, Canada: 1996-2006. J Subst Abuse Treat, 
39(1), 22-31. doi: 10.1016/j.jsat.2010.03.008 
Nosyk, B., Marshall, B. D., Fischer, B., Montaner, J. S., Wood, E., & Kerr, T. (2012). 
Increases in the availability of prescribed opioids in a Canadian setting. Drug 
Alcohol Depend, 126(1-2), 7-12. doi: 10.1016/j.drugalcdep.2012.03.010 
Office of the Provincial Health Officer. (2013). BC Methadone Maintenance 
System Performance Measures 2011/2012 Retrieved from 
 25 
http://www2.gov.bc.ca/assets/gov/health/about-bc-s-health-care-system/office-of-the-
provincial-health-officer/reports-publications/special-reports/methadone-2011-12.pdf. 
Office of the Provincial Health Officer. (2017). BC Opioid Substitution Treatment 
System: Performance Measures 2014/2015 and 2015/2016. Retrieved from 
http://www2.gov.bc.ca/assets/gov/health/about-bc-s-health-care-system/office-of-the-
provincial-health-officer/reports-publications/special-reports/bc-ost-system-measures-14-
15-and-15-16.pdf. 
Payte, J. T. (1995). Opioid dependence: A practical guide to pharmacotherapy. 
(Vancouver, British Columbia).  
Perlman, D. C., Jordan, A. E., Uuskula, A., Huong, D. T., Masson, C. L., 
Schackman, B. R., & Des Jarlais, D. C. (2015). An international perspective on 
using opioid substitution treatment to improve hepatitis C prevention and care 
for people who inject drugs: Structural barriers and public health potential. Int J 
Drug Policy, 26(11), 1056-1063. doi: 10.1016/j.drugpo.2015.04.015 
Peters, P. J., Pontones, P., Hoover, K. W., Patel, M. R., Galang, R. R., Shields, J., . . 
. Indiana, H. I. V. O. I. T. (2016). HIV Infection Linked to Injection Use of 
Oxymorphone in Indiana, 2014-2015. N Engl J Med, 375(3), 229-239. doi: 
10.1056/NEJMoa1515195 
Rosado, J., Walsh, S. L., Bigelow, G. E., & Strain, E. C. (2007). Sublingual 
buprenorphine/naloxone precipitated withdrawal in subjects maintained on 
100mg of daily methadone. Drug Alcohol Depend, 90(2-3), 261-269. doi: 
10.1016/j.drugalcdep.2007.04.006 
Seymour, A., Black, M., Jay, J., Cooper, G., Weir, C., & Oliver, J. (2003). The role 
of methadone in drug-related deaths in the west of Scotland. Addiction, 98(7), 
995-1002.  
Small, W., Maher, L., Lawlor, J., Wood, E., Shannon, K., & Kerr, T. (2013). 
Injection drug users' involvement in drug dealing in the downtown eastside of 
Vancouver: social organization and systemic violence. Int J Drug Policy, 24(5), 
479-487. doi: 10.1016/j.drugpo.2013.03.006 
Spunt B, H. D., Lipton DS, Goldsmith DS. (1986). Methadone diversion: a new 
look. J Drug Issues, 16(4), 569-583.  
Srivastava, A., Kahan, M., & Nader, M. (2017). Primary care management of 
opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone? Can 
Fam Physician, 63(3), 200-205.  
 26 
Strang, J., Hall, W., Hickman, M., & Bird, S. M. (2010). Impact of supervision of 
methadone consumption on deaths related to methadone overdose (1993-2008): 
analyses using OD4 index in England and Scotland. BMJ, 341, c4851. doi: 
10.1136/bmj.c4851 
Strathdee, S. A., Palepu, A., Cornelisse, P. G., Yip, B., O'Shaughnessy, M. V., 
Montaner, J. S., . . . Hogg, R. S. (1998). Barriers to use of free antiretroviral 
therapy in injection drug users. JAMA, 280(6), 547-549.  
Substance Abuse and Mental Health Services Administration (2013). Drug Abuse 
Warning Network, 2011: National Estimates of Drug-Related Emergency 
Department Visits Retrieved from 
https://http://www.samhsa.gov/data/sites/default/files/DAWN2k11ED/DAWN2k11ED/
DAWN2k11ED.pdf. 
Suryaprasad, A. G., White, J. Z., Xu, F., Eichler, B. A., Hamilton, J., Patel, A., . . . 
Holmberg, S. D. (2014). Emerging epidemic of hepatitis C virus infections among 
young nonurban persons who inject drugs in the United States, 2006-2012. Clin 
Infect Dis, 59(10), 1411-1419. doi: 10.1093/cid/ciu643 
Tjagvad, C., Skurtveit, S., Linnet, K., Andersen, L. V., Christoffersen, D. J., & 
Clausen, T. (2016). Methadone-Related Overdose Deaths in a Liberal Opioid 
Maintenance Treatment Programme. Eur Addict Res, 22(5), 249-258. doi: 
10.1159/000446429 
Tyndall, M. W., Currie, S., Spittal, P., Li, K., Wood, E., O'Shaughnessy, M. V., & 
Schechter, M. T. (2003). Intensive injection cocaine use as the primary risk factor 
in the Vancouver HIV-1 epidemic. AIDS, 17(6), 887-893. doi: 
10.1097/01.aids.0000050859.71999.ae 
United Nations Office on Drugs and Crime. (2014).  New York: World drug 
report Retrieved from 
https://http://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf
. 
Walsh, S. L., June, H. L., Schuh, K. J., Preston, K. L., Bigelow, G. E., & Stitzer, M. 
L. (1995). Effects of buprenorphine and methadone in methadone-maintained 
subjects. Psychopharmacology (Berl), 119(3), 268-276.  
Webster, L. R., Cochella, S., Dasgupta, N., Fakata, K. L., Fine, P. G., Fishman, S. 
M., . . . Wakeland, W. (2011). An analysis of the root causes for opioid-related 
overdose deaths in the United States. Pain Med, 12 Suppl 2, S26-35. doi: 
10.1111/j.1526-4637.2011.01134.x 
 27 
Winstock, A. R., Lea, T., & Sheridan, J. (2008). Prevalence of diversion and 
injection of methadone and buprenorphine among clients receiving opioid 
treatment at community pharmacies in New South Wales, Australia. Int J Drug 
Policy, 19(6), 450-458. doi: 10.1016/j.drugpo.2007.03.002 
Wood, E., Kerr, T., Marshall, B. D., Li, K., Zhang, R., Hogg, R. S., . . . Montaner, J. 
S. (2009). Longitudinal community plasma HIV-1 RNA concentrations and 
incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ, 
338, b1649. doi: 10.1136/bmj.b1649 
Wood, E., Stoltz, J. A., Montaner, J. S., & Kerr, T. (2006). Evaluating 
methamphetamine use and risks of injection initiation among street youth: the 
ARYS study. Harm Reduct J, 3, 18. doi: 10.1186/1477-7517-3-18 
Wood, E., Tyndall, M. W., Spittal, P. M., Li, K., Kerr, T., Hogg, R. S., . . . 
Schechter, M. T. (2001). Unsafe injection practices in a cohort of injection drug 
users in Vancouver: Could safer injecting rooms help? Canadian Medical 
Association Journal, 165(4), 405-410.  
Zibbell, J. E., Hart-Malloy, R., Barry, J., Fan, L., & Flanigan, C. (2014). Risk factors 
for HCV infection among young adults in rural New York who inject 
prescription opioid analgesics. Am J Public Health, 104(11), 2226-2232. doi: 
10.2105/AJPH.2014.302142 
 
 
 
 
 
  
 28 
 
Table 1: Baseline characteristics stratified by diverted methadone availability among opioid users in Vancouver, 
Canada, 2005-2015 (n = 2092).  
 
Diverted methadone Availability 
      p-value 
Not Available   
(n=1104) 
n (%) 
Delayed Availability 
(n=387) 
n (%) 
Immediate Availability 
(n=601) 
n (%) 
Age (per additional year)     
Median 37.9  34.1  38.8  <0.001 
IQR (26.8 – 45.9) (23.7 – 44.3) (28.3 – 46.9)  
White     
Yes 671 (50.7) 271 (20.5) 382 (28.9) 0.126 
No 433 (56.4) 116 (15.1) 219 (28.5)  
Female     
Yes 412 (56.6) 119 (16.4) 196 (27.0) 0.030 
No 692 (50.7) 268 (19.6) 405 (29.7)  
HomelessA     
Yes 472 (49.9) 186 (19.6) 289 (30.5) 0.022 
No 630 (55.3) 199 (17.5) 310 (27.2)  
DTES residenceA,B    
Yes 662 (49.8) 212 (16.0) 455 (34.2) <0.001 
No 442 (57.9) 175 (22.9) 146 (19.2)  
Dealing drugsA    
Yes 377 (44.8) 155 (18.4) 309 (36.8) <0.001 
No 727 (58.1) 232 (18.5) 292 (23.4)  
Sex work involvementA    
Yes 186 (53.7) 65 (18.8) 95 (27.5) 0.570 
No 911 (52.5) 320 (18.4) 505 (29.1)  
Prescription opioid injectionA    
≥ daily 65 (44.5) 23 (15.8) 58 (39.7) 0.006 
< daily 1036 (53.4) 364 (18.8) 541 (27.8)  
Injection heroin useA    
≥ daily 346 (52.5) 111 (16.9) 201 (30.6) 0.491 
< daily 756 (52.8) 276 (19.3) 400 (27.9)  
Injection cocaine useA    
≥ daily 90 (53.6) 19 (11.3) 59 (35.1) 0.398 
< daily 1010 (52.6) 368 (19.2) 542 (28.2)  
Injection methamphetamine useA    
≥ daily 58 (40.6) 37 (25.8) 48 (33.6) 0.152 
< daily 1042 (53.6) 350 (18.0) 552 (28.4)  
Non-injection crack useA    
 29 
≥ daily 402 (52.3) 121 (15.8) 245 (31.9) 0.152 
< daily 701 (53.0) 265 (20.1) 356 (26.9)  
Non-fatal overdoseA    
Yes 121 (48.7) 48 (19.4) 79 (31.9) 0.174 
No 980 (53.3) 339 (18.4) 521 (28.3)  
Participated in MMTA    
Yes 402 (48.2) 162 (19.5) 269 (32.3) <0.001 
No 697 (55.9) 223 (17.9) 328 (26.2)  
Unable to access addiction treatmentA    
Yes 83 (40.7) 49 (24.0) 72 (35.3) 0.001 
No 1015 (54.1) 336 (17.9) 525 (28.0)  
IncarcerationA    
Yes 214 (50.8) 82 (19.5) 125 (29.7) 0.481 
No 882 (53.1) 305 (18.3) 475 (28.6)  
Cohort designation    
ACCESS 301 (50.3) 114 (19.0) 184 (30.7) 0.307 
ARYS 
VIDUS 
239 (49.4) 
564 (55.9) 
126 (26.0) 
147 (14.6) 
119 (24.6) 
298 (29.5) 
 
A denotes activities in the six months prior to follow-up interview 
BDTES – Downtown Eastside; MMT – Methadone Maintenance Therapy; ACCESS – AIDS Care Cohort to Evaluate Exposure to Survival 
Services; VIDUS – Vancouver Injection Drug Users Study; ARYS – At-Risk Youth Study. 
 Table 2. Bivariable and multivariable GEE analysis of factors associated with methadone availability 
 Model 1. Immediate availability vs. not available  Model 2. Delayed availability vs. not available 
 Unadjusted  Adjusted             Unadjusted Adjusted 
Characteristic 
Odds Ratio 
(95% CI) 
p - value Odds Ratio 
(95% CI) 
p - value  
 
Odds Ratio 
(95% CI) 
p - value Odds Ratio 
(95% CI) 
p - value 
Calendar year            
(per year later)  1.18 (1.16 – 1.20) <0.001 1.21 (1.19 – 1.23) <0.001  1.28 (1.18 – 1.22) <0.001 1.21 (1.19 – 1.23) <0.001 
Age             
(per 10 years older) 1.45 (1.37 – 1.53) <0.001 1.16 (1.08 – 1.24)     <0.001  1.16 (1.10 – 1.22) <0.001   
White            
(yes vs. no) 1.14 (1.01 – 1.28) 0.029    1.45 (1.28 – 1.64) <0.001   
Sex            
(male vs. female) 1.26 (1.12 – 1.42) <0.001    1.28 (1.13 – 1.45) <0.001   
HomelessA            
(yes vs. no) 0.83 (0.76 – 0.91) <0.001    0.80 (0.72 – 0.88) <0.001   
DTES residenceA,B            
(yes vs. no) 1.51 (1.37 – 1.66) <0.001 1.65 (1.50 – 1.82) <0.001  0.90 (0.82 – 1.00) 0.041   
Dealing drugsA            
(yes vs. no) 1.25 (1.14 – 1.37) <0.001 1.62 (1.47 – 1.78) <0.001  1.28 (1.15 – 1.42) <0.001 1.57 (1.41 – 1.75) <0.001 
Sex work 
involvementA 
           
(yes vs. no) 0.92 (0.79 – 1.06) 0.255    0.99 (0.85 – 1.16) 0.905   
Prescription opioid 
injectionA 
    
       
(≥ daily vs. <daily) 1.27 (1.07 – 1.51) 0.005    1.18 (0.96 – 1.47) 0.125   
Injection heroin useA            
(≥ daily vs. <daily) 1.01 (0.91 – 1.12) 0.827    0.93 (0.83 – 1.04) 0.214   
Injection cocaine useA            
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(≥ daily vs. <daily) 1.07 (0.92 – 1.25) 0.362    0.82 (0.69 – 0.98) 0.032   
Injection 
methamphetamine 
useA 
    
       
(≥ daily vs. <daily) 1.17 (0.98 – 1.41) 0.078    1.21 (0.99 – 1.47) 0.063   
Non-injection crack 
useA 
    
       
(≥ daily vs. <daily) 0.92 (0.84 – 1.01) 0.075    0.78 (0.70 – 0.87) <0.001   
Non-fatal overdoseA            
(yes vs. no) 1.01 (0.88 – 1.17) 0.891    1.13 (0.96 – 1.33) 0.147   
Participated in 
MMTA 
           
(yes vs. no) 1.51 (1.37 – 1.66) <0.001    1.57 (1.42 – 1.75) <0.001   
Unable to access 
addiction treatmentA 
    
       
(yes vs. no) 1.03 (0.89 – 1.19) 0.695    1.19 (1.00 – 1.41) 0.049   
IncarcerationA            
(yes vs. no) 0.82 (0.73 – 0.93) 0.001    0.89 (0.77 – 1.02) 0.101   
Cohort designation          
(ACCESS vs. VIDUS) 
 
0.98 (0.86 – 1.10) 
 
0.710 
 
0.85 (0.75 – 0.96) 
 
0.010 
 
 
 0.98 (0.86 – 1.11) 
 
 
      0.721 
 
 
  
(ARYS vs. VIDUS) 0.50 (0.42 – 0.60) <0.001 1.16 (1.08 – 1.24) <0.001  0.99 (0.84 – 1.17) 0.931   
ARefers to the 6-month period before the interview. 
BDTES – Downtown Eastside; MMT – Methadone Maintenance Therapy; ACCESS – AIDS Care Cohort to Evaluate Exposure to Survival 
Services; VIDUS – Vancouver Injection Drug Users Study; ARYS – At-Risk Youth Study. 
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Figure 1. Trends in diverted methadone availability over the study period.  
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